Bioregnum — The view from Endpoints News
Allergan CEO Brent Saunders scored some heavyweight kudos last fall with a social contract that condemned predatory drug pricing by the likes of Martin Shkreli and outlined the company’s commitment to R&D and access. But on Friday he squandered whatever moral clout he may have earned along the way with a legal gambit that looked too clever by half.
Here’s what happened:
Facing a patent challenge to its franchise drug Restasis, Allergan handed over the patents to the St. Regis Mohawk Tribe, which has sovereign immunity against inter partes review challenges. The tribe — best known for its casino ops — handed back an exclusive license to the drug, collected $13.75 million and can look forward to millions more in royalties each year, unless the courts toss it all out as a cynical ploy cooked up by attorneys.
This had all the ingredients any reporter looks for in an attention-grabbing story.
What you get are some freshly baked goods from a long line of publications, including the New York Times, the Wall Street Journal, CNBC, etc., etc., etc.
“I believe it’s novel,” Allergan CEO Brent Saunders told CNBC. “The actions today really allow us to focus the defense of the Restasis patents in the federal court system and avoid the double jeopardy created by the IPR system.”
A car salesman I knew in Texas once told me if it doesn’t look good in a headline, don’t do it.
Allergan just vaulted that line.
The tribe, meanwhile, is offering its patent protection services to anyone else in the pharma industry that would like to shift their patents to their protected tribal lands — in exchange for a hefty fee of course.
Image: Brent Saunders Getty
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 32,300+ biopharma pros who read Endpoints News by email every day.Free Subscription